The drugs, Mounjaro and copyright, represent injectable treatments generally prescribed for treating adult-onset diabetes, but they have unique actions. Saxenda operates by copying a natural hormone, GLP-1, to boost insulin production and decrease hunger. Conversely, Mounjaro integrates GLP-1 act